Therefore, we conclude that m6a-related mRNAs, especially METTL14, IGFBP2, and FTO, can influence the clinical outcome of HCC by altering tumor cell proliferation and survival. This evidence concerns the gene IGFBP2 and hepatocellular carcinoma.